Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
about
Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.Hepatitis C: a review for primary care physiciansInterferon for interferon nonresponding and relapsing patients with chronic hepatitis CHigh versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort studyPhysicians' preference values for hepatitis C health states and antiviral therapy: a surveyChronic hepatitis C: This and the new era of treatmentA New Twist to a Chronic HCV Infection: Occult Hepatitis CCharacterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli.Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapyChronic viral hepatitis C: management updateLong term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrenceProlonged Therapy of Advanced Chronic Hepatitis C with Low-Dose PeginterferonSustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibodyClinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patientsInterpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis CAPASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Occult infection with hepatitis C virus: friend or foe?Cerebral dysfunction in chronic hepatitis C infection.Interferon for interferon naive patients with chronic hepatitis C.Treatment of hepatitis C. The 2002 French consensus.WITHDRAWN: Ribavirin with or without alpha interferon for chronic hepatitis C.Occult hepatitis C: how convincing are the current data?Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference.Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment.Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis CThe hepatic flaviviridae: summary.Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.Long-term viral negativity after interferon for chronic hepatitis C virus infection in hemodialysis.Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection.Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C.Treatment of hepatitis C with interferon and ribavirin.Treatment of hepatitis C virus infectionTreatment of chronic hepatitis C in haemophilia patients.Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.New antiviral therapies for chronic hepatitis CSustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.Evolution of interferon-based therapy for chronic hepatitis C.Hepatitis C: a hepatologist's approach to an infectious disease.Predicting the probable outcome of treatment in HCV patients.
P2860
Q22305832-5C4EDC30-8221-406C-AC52-3E174A9475ACQ22306040-19F30D21-8E27-4D14-AC5D-0C5F1FB19759Q24201588-44DFD64B-EA9C-4A99-9CF3-5C318FD0E223Q24799492-15DD9936-4E6B-427E-8BEC-3B67B19DBDE2Q24802683-A6895F19-FD19-4367-B4D7-367EA3F40210Q26775011-21B10A85-585A-46A0-BFC3-D435F57DA532Q26798189-D2CE4B20-58C9-4065-9359-D196C788317EQ27469346-F70741D8-A45E-4946-8101-A3BD2E0FF43BQ27469660-69147BB6-E581-428E-8EF4-378BCAD7631BQ27469719-E34DFD17-D3EF-4223-8B54-4ED700542301Q27471844-81A958E6-DFF0-4EF1-905E-5DC11E4F1B98Q27477988-DCF37191-38E9-4013-81B1-09B4A93219CDQ27487518-DD4B5621-ADD4-4E75-AFB4-6DCA7393E83EQ27488912-61DCE196-DD52-4F69-9E4F-2CD1CB51B3C7Q27489398-CE94A636-5DE7-4C4A-B93A-62EE5294EDF3Q27490792-2FC7A782-210C-49C6-8A27-A53B060B456FQ30250088-95B8CF91-25F5-4D2B-99D8-9A7831989C5EQ30416187-8E5B2892-C18B-4CE0-8F24-B1FB746C12D0Q30773516-E7155B97-33F8-49BF-A3CE-ED9C201B60B3Q31083635-A576F414-560F-4F91-872F-F6777DF38B9CQ33195269-599B4435-22E7-4ADE-8019-733B31E94704Q33291074-208CC36B-CE0D-4D9D-845A-453FA0FE2BCDQ33395436-8A108235-4788-4577-9B10-75871A03ECE2Q33670338-C96693CD-8EAF-4742-BA4C-AF6B34670CC7Q33869545-2D2BBF75-CC11-4FF8-B919-96FB473F7602Q33869578-59B8AF05-0200-4F66-8225-32EB335DBFAEQ33888790-F081D682-66FC-4833-A24F-D1094286852CQ33947375-D3C13373-F435-4F94-89DB-C2AB981FF9A1Q33969758-8BE6A7FD-210A-49EC-B111-159B816FCC75Q33981422-E05BD131-606E-4BD1-BA89-98038C72327DQ33988105-7DBEA445-8558-458C-91D5-34B5C65877E9Q33988146-A597BB54-16A2-4C0E-B90C-10F1FD38659BQ34099424-AF88F985-1FE1-49F8-A5FD-08F1D27EF72BQ34107035-463634AD-D130-4883-BF2E-9571FF418ED1Q34125554-98A73066-1DC8-4AF5-B796-90307A14C7A1Q34130399-97180A83-C404-4E97-B2DB-2DA746CE1566Q34172595-92B23D6A-889C-4449-BA19-DA5CECAAA816Q34342092-D236EB28-76BC-4A1C-833D-CF17076DA760Q34398551-1E20FCDD-94D9-4179-9D42-DDD535362DA8Q34409039-E50BBD09-FE3E-4108-BDF6-434567315F3C
P2860
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Long-term histologic improveme ...... e to interferon-alpha therapy.
@en
Long-term histologic improveme ...... e to interferon-alpha therapy.
@nl
type
label
Long-term histologic improveme ...... e to interferon-alpha therapy.
@en
Long-term histologic improveme ...... e to interferon-alpha therapy.
@nl
prefLabel
Long-term histologic improveme ...... e to interferon-alpha therapy.
@en
Long-term histologic improveme ...... e to interferon-alpha therapy.
@nl
P2093
P1476
Long-term histologic improveme ...... e to interferon-alpha therapy.
@en
P2093
C Castelnau
J P Benhamou
M Martinot
P304
P356
10.7326/0003-4819-127-10-199711150-00003
P407
P577
1997-11-01T00:00:00Z